Cadila Healthcare has received an approval to raise funds through various sources. The board of directors at its meeting held on June 26, 2017 has approved for the same. The board has approved to raise funds by issue of Equity Shares / convertible Bonds / Debentures through Qualified Institutional Placement [QIP] / GDR / ADR, for an aggregate amount up to Rs 10,000 crore.
Besides, the board also approved to issue Secured / Unsecured Redeemable Non-Convertible Debentures / Foreign Currency Bonds on Private Placement Basis for an amount up to Rs 3,500 crore in the Financial Year 2017-2018 and to issue Foreign Currency Bond / Foreign Currency Convertible Bonds.
Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.
